Maria Raptis, Michael Frese, Julia Zhu and Marta Navarro Hernández discuss the continuing attention on whether the competition authorities’ existing toolbox for review suffices as their ability to review pharmaceutical deals increases. In March 2021, for example, several authorities in North America and Europe launched the Multilateral Pharmaceutical Merger Task Force to update their approaches to analyzing the effects of pharmaceutical mergers, in particular what factors should be considered, the sufficiency of existing theories of harm, legal standards and remedies. The authors review recent developments in those areas in the EU, U.S. and Asia Pacific regions.
An extract from GCR’s The Guide to Life Sciences – Second Edition. The whole publication is available at https://globalcompetitionreview.com/guide/guide-life-sciences/second-edition.